177 related articles for article (PubMed ID: 33817379)
21. Nestin-positive stem cells in neurofibromas from patients with neurofibromatosis type 1-tumorigenic or incidental?
Pongpudpunth M; Bhawan J; Al-Natour SH; Mahalingam M
Am J Dermatopathol; 2010 Aug; 32(6):574-7. PubMed ID: 20520523
[TBL] [Abstract][Full Text] [Related]
22. Treatment of cutaneous neurofibromas with carbon dioxide laser: Technique and patient experience.
Peltonen S; Jannic A; Wolkenstein P
Eur J Med Genet; 2022 Jan; 65(1):104386. PubMed ID: 34768015
[TBL] [Abstract][Full Text] [Related]
23. Complications of Neurofibromatosis 1 (NF1) in an Adult With Multiple Comorbidities.
Nnomadim OP; Bustamante Helfrich B
Cureus; 2021 Jul; 13(7):e16512. PubMed ID: 34430126
[TBL] [Abstract][Full Text] [Related]
24. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors.
Beert E; Brems H; Daniëls B; De Wever I; Van Calenbergh F; Schoenaers J; Debiec-Rychter M; Gevaert O; De Raedt T; Van Den Bruel A; de Ravel T; Cichowski K; Kluwe L; Mautner V; Sciot R; Legius E
Genes Chromosomes Cancer; 2011 Dec; 50(12):1021-32. PubMed ID: 21987445
[TBL] [Abstract][Full Text] [Related]
25. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.
Robertson KA; Nalepa G; Yang FC; Bowers DC; Ho CY; Hutchins GD; Croop JM; Vik TA; Denne SC; Parada LF; Hingtgen CM; Walsh LE; Yu M; Pradhan KR; Edwards-Brown MK; Cohen MD; Fletcher JW; Travers JB; Staser KW; Lee MW; Sherman MR; Davis CJ; Miller LC; Ingram DA; Clapp DW
Lancet Oncol; 2012 Dec; 13(12):1218-24. PubMed ID: 23099009
[TBL] [Abstract][Full Text] [Related]
26. Cutaneous squamous cell carcinoma in a patient with neurofibromatosis type 1: A case report.
Ishida M; Okabe H
Oncol Lett; 2013 Oct; 6(4):878-880. PubMed ID: 24137429
[TBL] [Abstract][Full Text] [Related]
27. New insights into the neurofibroma tumor cells of origin.
Li S; Chen Z; Le LQ
Neurooncol Adv; 2020 Jul; 2(Suppl 1):i13-i22. PubMed ID: 32642729
[TBL] [Abstract][Full Text] [Related]
28. Natural course and characteristics of cutaneous neurofibromas in neurofibromatosis 1.
Ehara Y; Yamamoto O; Kosaki K; Yoshida Y
J Dermatol; 2018 Jan; 45(1):53-57. PubMed ID: 28891076
[TBL] [Abstract][Full Text] [Related]
29. Spatiotemporal Loss of
Chen Z; Mo J; Brosseau JP; Shipman T; Wang Y; Liao CP; Cooper JM; Allaway RJ; Gosline SJC; Guinney J; Carroll TJ; Le LQ
Cancer Discov; 2019 Jan; 9(1):114-129. PubMed ID: 30348677
[TBL] [Abstract][Full Text] [Related]
30. Progesterone and Estrogen Receptors in Neurofibromas of Patients with NF1.
Geller M; Mezitis SG; Nunes FP; Ribeiro MG; Araújo AP; Bronstein MD; Siqueira-Batista R; Gomes AP; Oliveira L; Cunha KS
Clin Med Pathol; 2008; 1():93-7. PubMed ID: 21876657
[TBL] [Abstract][Full Text] [Related]
31. A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.
Nguyen HTL; Kohl E; Bade J; Eng SE; Tosevska A; Al Shihabi A; Tebon PJ; Hong JJ; Dry S; Boutros PC; Panossian A; Gosline SJC; Soragni A
Cell Rep Methods; 2024 May; 4(5):100772. PubMed ID: 38744290
[TBL] [Abstract][Full Text] [Related]
32. C2 neurofibromas in neurofibromatosis type 1: genetic and imaging characteristics.
Waqar M; Huson S; Evans DG; Ealing J; Karabatsou K; George KJ; Soh C
J Neurosurg Spine; 2018 Oct; 30(1):126-132. PubMed ID: 30485203
[TBL] [Abstract][Full Text] [Related]
33. Target Product Profile for Cutaneous Neurofibromas: Clinical Trials to Prevent, Arrest, or Regress Cutaneous Neurofibromas.
Ly I; Romo CG; Gottesman S; Kelly KM; Kornacki D; York Z; Lee SY; Rhodes SD; Staedtke V; Steensma MR; Blakeley JO; Wolkenstein P
J Invest Dermatol; 2023 Aug; 143(8):1388-1396. PubMed ID: 37294242
[TBL] [Abstract][Full Text] [Related]
34. Somatic loss of wild type NF1 allele in neurofibromas: Comparison of NF1 microdeletion and non-microdeletion patients.
De Raedt T; Maertens O; Chmara M; Brems H; Heyns I; Sciot R; Majounie E; Upadhyaya M; De Schepper S; Speleman F; Messiaen L; Vermeesch JR; Legius E
Genes Chromosomes Cancer; 2006 Oct; 45(10):893-904. PubMed ID: 16830335
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms of loss of heterozygosity in neurofibromatosis type 1-associated plexiform neurofibromas.
Steinmann K; Kluwe L; Friedrich RE; Mautner VF; Cooper DN; Kehrer-Sawatzki H
J Invest Dermatol; 2009 Mar; 129(3):615-21. PubMed ID: 18800150
[TBL] [Abstract][Full Text] [Related]
36. Validating Techniques for Measurement of Cutaneous Neurofibromas: Recommendations for Clinical Trials.
Thalheimer RD; Merker VL; Ly KI; Champlain A; Sawaya J; Askenazi NL; Herr HP; Da JLW; Jordan JT; Muzikansky A; Pearce EM; Sakamoto FH; Blakeley JO; Anderson RR; Plotkin SR;
Neurology; 2021 Aug; 97(7 Suppl 1):S32-S41. PubMed ID: 34230197
[TBL] [Abstract][Full Text] [Related]
37. Assessing interobserver variability and accuracy in the histological diagnosis and classification of cutaneous neurofibromass.
Ortonne N; Carroll SL; Rodriguez FJ; Miller DC; Nazarian RM; Blakeley JO; Madaj ZB; Verma SK; Stemmer-Rachamimov A
Neurooncol Adv; 2020 Jul; 2(Suppl 1):i117-i123. PubMed ID: 32642737
[TBL] [Abstract][Full Text] [Related]
38. Considerations for development of therapies for cutaneous neurofibroma.
Verma SK; Riccardi VM; Plotkin SR; Weinberg H; Anderson RR; Blakeley JO; Jarnagin K; Lee J
Neurology; 2018 Jul; 91(2 Suppl 1):S21-S30. PubMed ID: 29987132
[TBL] [Abstract][Full Text] [Related]
39. Synchronous Upper Intestinal Neurofibromas and Duodenal Periampullary Well-Differentiated Neuroendocrine Tumor Associated With Neurofibromatosis 1.
Balmer JC; Mikhaylov Y; Lewin DN; Mahvi DM; Ramsay Camp E
Am Surg; 2021 Jan; 87(1):128-130. PubMed ID: 32856931
[TBL] [Abstract][Full Text] [Related]
40. Sporadic Neurofibroma of the Tongue Unassociated with Neurofibromatosis Type I: A Clinicopathologic Study of Ten Cases.
Thompson LDR; Koh SS; Lau SK
Head Neck Pathol; 2020 Jun; 14(2):374-380. PubMed ID: 31111316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
